Hostname: page-component-7c8c6479df-995ml Total loading time: 0 Render date: 2024-03-28T18:18:52.640Z Has data issue: false hasContentIssue false

Migraine Prevalence, Treatment and Impact: The Canadian Women and Migraine Study

Published online by Cambridge University Press:  02 December 2014

Lara J. Cooke*
Affiliation:
Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
Werner J. Becker
Affiliation:
Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
*
Department of Clinical Neurosciences, 12th Floor, Foothills Medical Center, 1403-29th St NW, Calgary, Alberta, T2N 2T9, Canada.
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

The prevalence of migraine headache varies somewhat across geographic regions. The last Canadian population-based study of migraine was in 1994. We report the findings of the Canadian Women and Migraine Survey. In addition to reporting migraine prevalence in Canadian women, the survey identified current consultation and treatment practices of women with migraine, and the psychological burden of migraine.

Methods:

The survey was conducted with a population-based sample of 1210 women using standard telephone research methods. Headache diagnoses were based on the International Headache Society (IHS) Classification.

Results:

Calculated prevalence of migraine headache was 26%. Only 51% of women with migraine had consulted a physician about their headaches. Women with migraines rely on over-the-counter medications and non-specific prescription medications. Less than 10% of women with migraine use triptans/dihydroergotamine for primary treatment. Ninety seven percent of women with migraine reported at least one psychosocial impact resulting from migraines.

Conclusions:

The prevalence of migraine in Canadian women appears static, and is again shown to be slightly higher than that reported in the United States. As in other epidemiologic studies, many women with migraine do not seek medical help for their headaches and perhaps as a result, few are using migraine-specific medications to treat their headaches. The impact of migraine on Canadian women is substantial with almost all women with migraine reporting adverse psychosocial effects of migraines on their lives.

Résumé:

RÉSUMÉ:Contexte:

La prévalence de la migraine varie selon les régions. La dernière étude canadienne de population sur la migraine date de 1994. Nous rapportons les observations de la Canadian Women and Migraine Survey. Cette enquète a identifié entre autres les habitudes de consultation et de traitement actuels des femmes atteintes de migraine et a évalué le fardeau psychologique de la migraine.

Méthodes:

Cette enquète a été effectuée chez un échantillon de 1210 femmes provenant de la population générale, au moyen de méthodes standards de recherche téléphonique. Les diagnostics de céphalée étaient basés sur la classification de laSociété internationale de la céphalée.

Résultats:

La prévalence de la migraine était de 26%. Seulement 51% des femmes atteintes de migraine avaient consulté un médecin au sujet de leurs céphalées. Les femmes atteintes de migraine ont recours à des médicaments sans ordonnance et à des médicaments sous prescription qui ne sont pas spécifiques de la migraine. Moins de 10% des femmes atteintes de migraine utilisaient des triptans/de la dihydroergotamine comme traitement primaire. Quatre-vingt-dix-sept pour cent des femmes atteintes de migraine ont rapporté au moins un impact psychosocial de leurs migraines.

Conclusions:

La prévalence de la migraine chez les femmes canadiennes semble stable et nous démontrons encore une fois qu’elle est légèrement plus élevée que celle rapportée aux États-Unis. Plusieurs femmes atteintes de migraine ne consultent pas un médecin pour leurs céphalées, comme on l’a d’ailleurs observé dans d’autres études épidémiologiques, ce qui explique sans doute que peu utilisent des médicaments spécifiques de la migraine pour traiter leurs céphalées. L’impact de la migraine chez les femmes canadiennes est substantiel, presque toutes les femmes atteintes de migraine ayant rapporté des effets psychosociaux négatifs des migraines dans leur vie.

Type
Original Article
Copyright
Copyright © The Canadian Journal of Neurological 2010

References

1. O’Brien, B, Goeree, R, Streiner, D. Prevalence of migraine headache in Canada: a population-based survey. Int J Epidem. 1994;23(5):10206.Google Scholar
2. Dowson, AJ, Tepper, SJ, Baos, V, Baudet, F, D’Amico, D, Kilminster, S. Identifying patients who require a change in their acute migraine treatment: The Migraine Assessment of Current Therapy (Migraine-ACT) questionnaire. Curr Med Res Opin. 2004;20:11255.Google Scholar
3. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia.1988; 8 Suppl 7:196.Google Scholar
4. Pryse-Phillips, W, Findlay, H, Tugwell, P, Edmeads, J, Murray, TJ, Nelson, RF. A Canadian population survey on the clinical, epidemiologic, and societal impact of migraine and tension-type headache. Can J Neurol Sci. 1992;19:3339.Google Scholar
5. Stewart, WF, Lipton, RB, Celentano, DD, Reed, ML. Prevalence of migraine headache in the United States. Relation to age, income race, and other sociodemographic factors. JAMA. 1992;267:649.Google Scholar
6. Lipton, RB, Stewart, WF, Diamond, S, Diamond, ML, Reed, M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41: 64657.Google Scholar
7. Lipton, RB, Scher, AI, Kolodner, K, Liberman, J, Steiner, TJ, Stewart, WF. Migraine in the United States: epidemiology and patterns of health care use. Neurology. 2002;58:88594.Google Scholar
8. Steiner, TJ, Scher, AI, Stewart, WF, Kolodner, K, Liberman, J, Lipton, RB. The prevalence of adult migraine in England and its relationships to major sociodemographic characteristics. Cephalalgia. 2003;23(7):51927.Google Scholar
9. Radtke, A, Neurhauser, H. Prevalence and burden of headache and migraine in Germany. Headache. 2009;49(1):7989.CrossRefGoogle ScholarPubMed
10. Henry, P, Auray, JP, Gaudin, AF, Dartigues, JF, Duru, G, Lanteri-Minet, M, et al. Prevalence and clinical characteristics of migraine in France. Neurology. 2002;59:2327.Google Scholar
11. Russell, MB, Kristiansen, HA, Staltyte-Benth, J, Kvaerner, KJ. A cross-sectional population-based survey of migraine and headache in 21,177 Norwegians: the Akershus sleep apnea project. J Headache Pain. 2008;9:33947.Google Scholar
12. Bigal, ME, Lipton, RB. The epidemiology, burden, and comorbidities of migraine. Neurol Clin. 2009;27:32134.Google Scholar
13. Edmeads, J, Findlay, H, Tugwell, P, Pryse-Phillips, W, Nelson, RF, Murray, TJ. Impact of migraine and tension-type headache on lifestyle, consulting behaviour, and medication use: a Canadian population survey. Can J Neurol Sci. 1993;20:1317.CrossRefGoogle ScholarPubMed
14. Lipton, RB, Bigal, ME, Kolodner, K, Stewart, WF, Liberman, JN, Steiner, TJ. The family impact of migraine: population-based studies in the USA and UK. Cephalalgia. 2003;23(6):42940.Google Scholar
15. MacGregor, EA, Brandes, J, Eikermann, A. Migraine prevalence and treatment patterns: the Global Migraine and Zolmitriptan Evaluation Study. Headache. 2003;43:1926.CrossRefGoogle Scholar
16. Duncan, CW, Watson, DPB, Stein, A. Diagnosis and management of headache in adults: summary of SIGN guideline. BMJ. 2008;337:a232934.CrossRefGoogle ScholarPubMed
17. Hu, XH, Markson, LE, Lipton, RB, Stewart, WF, Berger, ML. Burden of migraine in the United States. Arch Intern Med. 1999;159;81318.CrossRefGoogle ScholarPubMed
18. Dueland, AN, Leira, R, Cabelli, ST. The impact of migraine on psychological well-being of young women and their communication with physicians about migraine: a multinational study. Curr Med Res Opin. 2005;21(8):1297305.Google Scholar